Monday, June 19, 2017 8:05:44 AM
SEC Grants Heat Biologics Request For Confidential Treatment
BY Midnight Trader
— 3:59 PM ET 06/14/2017
03:59 PM EDT, 06/14/2017 (MT Newswires) -- Heat Biologics ( HTBX )
Made request for confidential treatment for information it excluded from a Form 10-K filed on May 3, 2017 has been granted by the Securities and Exchange Commission.
Heat Biologics
HTBX said the information qualifies as confidential commercial or financial information under the Freedom of Information Act.
According to the SEC, the excluded information will not be released to the public through May 3, 2022.
Price: 0.63, Change: -0.01, Percent Change: -1.31
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
June 14, 2017
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Heat Biologics, Inc.
File No. 1-35994 - CF#35080
_____________________
Heat Biologics, Inc. submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 8-K filed
on May 3, 2017.
Based on representations by Heat Biologics, Inc. that this information qualifies as
confidential commercial or financial information under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly
disclose it. Accordingly, excluded information from the following exhibits will not be
released to the public for the time periods specified:
Exhibit 10.2 through May 3, 2022
Exhibit 10.3 through May 3, 2022
Exhibit 10.4 through May 3, 2022
Exhibit 10.5 through May 3, 2022
Exhibit 10.6 through May 3, 2022
Exhibit 10.7 through May 3, 2022
Exhibit 10.8 through May 3, 2022
Exhibit 10.9 through May 3, 2022
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Brent J. Fields
Secretary
Recent NHWK News
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:59:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:07 PM
- NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:57:14 PM
- NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University • GlobeNewswire Inc. • 12/21/2023 01:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:47:34 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM